Thai Ho, MD, Oncology, Phoenix, AZ, Mayo Clinic Hospital

ThaiHuuHoMDPhD

Oncology Phoenix, AZ

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Internal Medicine, Mayo Medical School

Dr. Ho is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ho's full profile

Already have an account?

Skills & Expertise

  • Alternative Splicing, RNA Splicing, Cell Line, Histone Code, Kidney Neoplasms, Renal cell carcinoma, Therapeutics, Urologic oncology, Hematologic oncology, General medical oncology, Urethral cancer

Education & Training

  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterFellowship, Hematology/Oncology, 2009 - 2012
  • Washington University - Barnes-Jewish Hospital
    Washington University - Barnes-Jewish HospitalResidency, Internal Medicine, 2006 - 2009
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2006

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2021
  • AZ State Medical License
    AZ State Medical License 2012 - 2023
  • TX State Medical License
    TX State Medical License 2009 - 2022
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Young Investigator Award ASCO
  • Paul Calabresi Career Development Award (K12) Mayo Clinic Cancer Center

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • Deciphering the Interplay Between H3K36 and DNA Methylation in Renal CancerNIH2018–2023
  • Reprogramming Chromatin Modifiers in Kidney CancerDepartment of Defense2017–2020
  • Functional characterization of pazopanib or sunitinib on T cell functionNovartis2017–2018
  • Study of a Newly Discovered Immune Cell in the Blood and Evaluation of Its Potential Medical ApplicationsDepartment of Defense2015–2016
  • Identifying Epigenetically Regulated Pathways to Target Kidney Cancer MetastasesNIH2013–2016
  • Papillary Renal Cell and Urothelial Carcinomas Sample SubmissionNational Institutes of Health2013–2014
  • The Role of SETD2, a Histone Methyltransferase, in the Development of Renal Cell CarcinomaConquer Cancer Foundation2011–2012

Professional Memberships

Hospital Affiliations